Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y Nutrición (35)

2023

  1. A new FGF15/19-mediated gut-to-heart axis controls cardiac hypertrophy

    Journal of Pathology, Vol. 261, Núm. 3, pp. 335-348

  2. Antagonic effect of ghrelin and LEAP-2 on hepatic stellate cell activation and liver fibrosis in obesity-associated nonalcoholic fatty liver disease

    European journal of endocrinology, Vol. 188, Núm. 7, pp. 564-577

  3. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome

    Biomedicine and Pharmacotherapy, Vol. 161

  4. Corrigendum: Role of NAFLD on the health related QoL response to lifestyle in patients with metabolic syndrome: The PREDIMED plus cohort(Front. Endocrinol., (2022), 13, (868795), 10.3389/fendo.2022.868795)

    Frontiers in Endocrinology

  5. Dietary Iron, Anemia Markers, Cognition, and Quality of Life in Older Community-Dwelling Subjects at High Cardiovascular Risk

    Nutrients, Vol. 15, Núm. 20

  6. Estimation of fatty liver disease clinical role on glucose metabolic remodelling phenotypes and T2DM onset

    European Journal of Clinical Investigation, Vol. 53, Núm. 10

  7. Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease

    Journal of Physiology and Biochemistry

  8. Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria

    International Journal of Molecular Sciences, Vol. 24, Núm. 15

  9. Repercussions of absolute and time-rated BMI “yo-yo” fluctuations on cardiovascular stress-related morbidities within the vascular-metabolic CUN cohort

    Frontiers in Endocrinology, Vol. 13

  10. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

  11. Uroguanylin prevents hepatic steatosis, mitochondrial dysfunction and fibrosis in obesity-associated NAFLD

    Metabolism: Clinical and Experimental, Vol. 147